source
- Microbiome startup Kanvas Biosciences secures $48 million to advance immunotherapy and malnutrition therapiesKanvas Biosciences announced it has closed a $48 million financing round to fund development of microbiome-based treatments targeting cancer immunotherapy response and severe malnutrition. The cap…
- J&J advances IBD combo to Phase 3 despite Phase 2 setbacksJohnson & Johnson said it will advance its experimental inflammatory bowel disease therapy, JNJ-4804, into Phase 3 trials even though the drug failed to meet primary endpoints in two Phase 2 studie…